Terms: = Breast cancer AND H3F3B, H3_3A, 3021, ENSG00000132475, P84243, H3_3B, MGC87783, MGC87782, H3F3
14 results:
1. Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
Wang J; Xia YC; Tian BX; Li JT; Li HY; Dong H; Li XG; Yu H; Zhu YY; Ma J; Jiang YJ; Jin GZ
Cancer; 2024 Apr; 130(S8):1424-1434. PubMed ID: 38217532
[TBL] [Abstract] [Full Text] [Related]
2. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
[TBL] [Abstract] [Full Text] [Related]
3. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract] [Full Text] [Related]
4. Oncologic Outcome of Endoscopic Assisted breast Surgery Compared with Conventional Approach in breast cancer: An Analysis of 3426 Primary Operable breast cancer Patients from Single Institute with and Without Propensity Score Matching.
Lai HW; Chen ST; Liao CY; Mok CW; Lin YJ; Chen DR; Kuo SJ
Ann Surg Oncol; 2021 Nov; 28(12):7368-7380. PubMed ID: 33974198
[TBL] [Abstract] [Full Text] [Related]
5. Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage breast cancer: A Network Meta-analysis.
John P; Osani MC; Kodali A; Buchsbaum R; Bannuru RR; Erban JK
Clin Breast Cancer; 2021 Feb; 21(1):e22-e37. PubMed ID: 32917538
[TBL] [Abstract] [Full Text] [Related]
6. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the breast International Group Trial 1-98.
Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
[TBL] [Abstract] [Full Text] [Related]
8. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
Bick U; Engel C; Krug B; Heindel W; Fallenberg EM; Rhiem K; Maintz D; Golatta M; Speiser D; Rjosk-Dendorfer D; Lämmer-Skarke I; Dietzel F; Schäfer KWF; Leinert E; Weigel S; Sauer S; Pertschy S; Hofmockel T; Hagert-Winkler A; Kast K; Quante A; Meindl A; Kiechle M; Loeffler M; Schmutzler RK;
Breast Cancer Res Treat; 2019 May; 175(1):217-228. PubMed ID: 30725383
[TBL] [Abstract] [Full Text] [Related]
9. The characteristics of breast cancer subtypes: implications for treatment guidelines and individualized treatment strategies in China.
Zheng S; Song QK; Ren Y; Feng WL; Kong YN; Huang R; Xu F; Li J; Zhang BN; Fan JH; He JJ; Qiao YL
Appl Immunohistochem Mol Morphol; 2014; 22(5):383-9. PubMed ID: 24162264
[TBL] [Abstract] [Full Text] [Related]
10. BRCA1 and p53 regulate critical prostate cancer pathways.
De Luca P; Moiola CP; Zalazar F; Gardner K; Vazquez ES; De Siervi A
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):233-8. PubMed ID: 23670255
[TBL] [Abstract] [Full Text] [Related]
11. Synthesis, and docking studies of some fused-quinazolines and quinazolines carrying biological active isatin moiety as cell-cycle inhibitors of breast cancer cell lines.
Radwan AA; Alanazi FK; Al-Dhfyan A
Drug Res (Stuttg); 2013 Mar; 63(3):129-36. PubMed ID: 23444171
[TBL] [Abstract] [Full Text] [Related]
12. Do thyroid disorders increase the risk of breast cancer?
Simon MS; Tang MT; Bernstein L; Norman SA; Weiss L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone K; Marchbanks PA; McDonald JA; Strom BL; Wilson HG; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1574-8. PubMed ID: 12496046
[TBL] [Abstract] [Full Text] [Related]
13. The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results.
Marchbanks PA; Mcdonald JA; Wilson HG; Burnett NM; Daling JR; Bernstein L; Malone KE; Strom BL; Norman SA; Weiss LK; Liff JM; Wingo PA; Burkman RT; Folger SG; Berlin JA; Deapen DM; Ursin G; Coates RJ; Simon MS; Press MF; Spirtas R
Ann Epidemiol; 2002 May; 12(4):213-21. PubMed ID: 11988408
[TBL] [Abstract] [Full Text] [Related]
14. Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells.
Laurance ME; Starr DB; Michelotti EF; Cheung E; Gonzalez C; Tam AW; Deikman J; Edwards CA; Bardwell AJ
Nucleic Acids Res; 2001 Feb; 29(3):652-61. PubMed ID: 11160886
[TBL] [Abstract] [Full Text] [Related]
